research · United Kingdom · Trial launch
REFINE-MS will study longer ocrelizumab treatment intervals
UCL Innovative Clinical Trials Unit · published 2026-06-01 · approved by our editors 9/7/2026
UCL has launched REFINE-MS to investigate whether some people with relapsing-remitting MS can receive ocrelizumab less often while maintaining disease control. The study compares treatment intervals. It has not established that patients should change their existing treatment schedules.
What this means
This is a trial announcement, not completed evidence supporting a change to current prescribing. Recruitment status should be checked at the trial’s own source.
Read the original
This is our short summary. The full article belongs to UCL Innovative Clinical Trials Unit (charity_or_research_institution).
Read the original articleA new trial for people living with relapsing-remitting multiple sclerosis launches in the UK